Karin Berger-Thürmel

Dr. Karin Berger-Thürmel

Department of Hematology, Oncology, Ludwig-Maximilian-University Hospital, Munich, Germany

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
SCSonja von Campenhausen
Sonja von Campenhausen
BBBernhard Bornschein
Bernhard Bornschein
RWRegina Wick
Regina Wick
KBKai Bötzel
Kai Bötzel
CSCristina Sampaio
Cristina Sampaio
RDRichard Dodel
Richard Dodel

1 January 2003 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
BSB. Schramm
B. Schramm
BEB. Ehlken
B. Ehlken
ASA. Smala
A. Smala
KQK. Quednau
K. Quednau
Karin Berger-ThürmelKarin Berger-Thürmel
Karin Berger-Thürmel
DND. Nowak
D. Nowak
The purpose of this study was to evaluate the cost of illness of moderate-to-severe atopic asthma and/or seasonal allergic rhinitis (SAR) in Germany from the perspective of third-party payers (TPP) and patients.Five-hundred patients (276 children/adolescents) with moderate-to-severe asthma and/or SAR were included in this cross-sectional study. Information was collected using a specific patient questionnaire and the abstraction of patient records.Overall, annual costs per patient increased with the severity of atopic asthma and if it was associated with SAR. The average annual cost of SAR was 1,089 per child/adolescent and 1,543 per adult. Annual costs of severe asthma plus SAR increased to 7,928 per child/adolescent and to 9,287 per adult. For TPPs, the main cost drivers were medication, hospitalisation, and rehabilitation. The most significant costs for patients were household modifications. For children/adolescents, 60–78% of the expenditures were direct costs, while in adults, 58% of expenditures were indirect costs. It was also observed that patients with moderate and severe asthma used inhaled corticosteroids less frequently than recommended by treatment guidelines.In summary, the total cost for patients increases with the severity of atopic asthma and/or seasonal allergic rhinitis and indirect costs represent a large proportion of the total cost.

1 January 2005 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
ASAnnika E. Spottke
Annika E. Spottke
MRMartin Reuter
Martin Reuter
OMOlaf Machat
Olaf Machat
BBBernhard Bornschein
Bernhard Bornschein
SCSonja von Campenhausen
Sonja von Campenhausen
RDRichard Dodel
Richard Dodel

1 March 2004 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
AIA. Ihbe-Heffinger
A. Ihbe-Heffinger
BEB. Ehlken
B. Ehlken
RBR. Bernard
R. Bernard
Karin Berger-ThürmelKarin Berger-Thürmel
Karin Berger-Thürmel
CPC. Peschel
C. Peschel
FLF. Lordick
F. Lordick
Background: Delayed chemotherapy-induced nausea and vomiting (CINV) remains a major adverse effect of cancer chemotherapy. We assessed, under current practice patterns, the occurrence and impact on healthcare resource utilization of CINV in patients receiving emetogenic chemotherapy. An additional aim of this study was to estimate costs imputable to CINV in the German healthcare environment. Materials and methods: This prospective, multi-center, cross-sectional cost-of-illness study was conducted in three hospitals and in three office-based facilities in Germany. Consecutive patients undergoing emetogenic chemotherapy (levels 4 or 5 according to Hesketh classification of emetogenicity) were enrolled. Data were obtained from preplanned chart reviews and from self-administered patient questionnaires. Analysis of direct costs was performed from the perspectives of third party payer (statutory sick fund), provider (hospital) and patients. Indirect costs were assessed on the basis of paid workdays lost. Results: During the 5-day observation period, 134 of 208 chemotherapy cycles observed (64.4%) were associated with at least one episode of nausea or vomiting. More patients experienced delayed than acute CINV (60.7% versus 32.8%), and more patients reported nausea than vomiting (62.5% versus 26.0%). A total of 68 patients (32.6%) utilized healthcare resources due to CINV. The most frequently used resources were rescue medications and outpatient hospital and office physician visits. Only one patient required hospitalization and only three patients lost workdays due to CINV. Average costs imputable to CINV per patient (with or without CINV) per treatment cycle incurred by third party payers and hospital providers were €49 and €48, respectively. Patient or treatment characteristics that were associated with high costs imputable to CINV were as follows: cisplatin-containing regimen; experience of emesis; and presence of delayed CINV. Conclusions: A substantial proportion of patients continue to experience CINV. This entails not only clinical but also economic consequences, and highlights a continuing need for improved utilization of existing antiemetic agents and for new, more efficacious treatments. The greatest improvements in patient care and potential for cost offset may be realized by preventing delayed CINV.

1 February 2011 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
SCSonja von Campenhausen
Sonja von Campenhausen
YWYaroslav Winter
Yaroslav Winter
ASAntonio Rodrigues e Silva
Antonio Rodrigues e Silva
CSChristina Sampaio
Christina Sampaio
EREvžen Růžička
Evžen Růžička
JRJens P. Reese
Jens P. Reese

1 January 2001 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
RDRichard C. Dodel
Richard C. Dodel
Karin Berger-ThürmelKarin Berger-Thürmel
Karin Berger-Thürmel
WOWolfgang H. Oertel
Wolfgang H. Oertel